History
The importance of TNF in the development of rheumatoid arthritis was originally demonstrated by George Kollias and colleagues in proof of principle studies in transgenic animal models.Infliximab was developed by Junming Le (b.1940) and Jan Vilček (b.1933) at New York University School of Medicine and in collaboration with Centocor, (now Janssen Biotech, Inc.)

Society and culture
Marketing
Remicade is marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the United States, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-Plough (now part of Merck & Co) elsewhere. Biosimilars
In June 2013, two biosimilar versions (Inflectra and Remsima) were submitted for approval in Europe, by Hospira and Celltrion Healthcare respectively. Both had a positive opinion from European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) for sale in the European Union (EU). Celltrion obtained marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries by September 2013. Inflectra was approved for use in the European Union in September 2013, and Remsima was approved for use in the European Union in October 2013.In Japan, Celltrion received marketing authorization for Remsima from Japans Ministry of Health, Labour and Welfare (MHLW) in July 2014.In India, Epirus Biopharmaceuticals obtained approval to produce biosimilar infliximab under the brand name "Infimab" (trail name BOW015).The U.S. Food and Drug Administration (FDA) approved Celltrion/Hospira/Pfizers Inflectra (infliximab-dyyb) in April 2016.
Although the US brand name is Inflectra, it is marketed in the European Union as Remsima.The FDA approved Samsung Bioepis Co., Ltd.s Renflexis (infliximab-abda) in April 2017.Biogen released another biosimilar, Flixabi, which was approved in Germany, the UK, and the Netherlands. Flixabi was approved for use in the European Union in May 2016.In December 2017, Ixifi (infliximab-qbtx) was approved in the United States.Zessly was approved for use in the European Union in May 2018.In December 2019, Avsola (infliximab-axxq) was approved in the United States.Avsola was approved for medical use in Canada in March 2020.In December 2021, Ixifi was approved for medical use in Canada. Availability/affordability
In the United States, infliximab is an expensive medication, costing about US$900 for a 100 mg dose, and is covered by almost every US medical insurance plan (though caps on many plans make it possible to be covered for only a subset of treatments in the course of a year). Infliximab is supplied as a sterile, white, lyophilized (freeze-dried) powder, so must be reconstituted and administered by a health care professional, usually in a hospital or office setting. For this reason, it is usually covered under major medical insurance rather than prescription drug coverage. The loading regimen for all approved indications occurs at weeks 0, 2, and 6 at the above dosages.In the UK, infliximab is available from the NHS for Crohns disease treatment provided three criteria are met.